Skin fibroblasts from pantothenate kinase-associated neurodegeneration patients show altered cellular oxidative status and have defective iron-handling properties.
Pantothenate kinase-associated neurodegeneration (PKAN) is a neurodegenerative disease belonging to the group of neurodegeneration with brain iron accumulation disorders. It is characterized by progressive impairments in movement, speech and cognition. The disease is inherited in a recessive manner due to mutations in the Pantothenate Kinase-2 (PANK2) gene that encodes a mitochondrial protein involved in Coenzyme A synthesis. To investigate the link between a PANK2 gene defect and iron accumulation, we analyzed primary skin fibroblasts from three PKAN patients and three unaffected subjects. The oxidative status of the cells and their ability to respond to iron were analyzed in both basal and iron supplementation conditions. In basal conditions, PKAN fibroblasts show an increase in carbonylated proteins and altered expression of antioxidant enzymes with respect to the controls. After iron supplementation, the PKAN fibroblasts had a defective response to the additional iron. Under these conditions, ferritins were up-regulated and Transferrin Receptor 1 (TfR1) was down-regulated to a minor extent in patients compared with the controls. Analysis of iron regulatory proteins (IRPs) reveals that, with respect to the controls, PKAN fibroblasts have a reduced amount of membrane-associated mRNA-bound IRP1, which responds imperfectly to iron. This accounts for the defective expression of ferritin and TfR1 in patients' cells. The inaccurate quantity of these proteins produced a higher bioactive labile iron pool and consequently increased iron-dependent reactive oxygen species formation. Our results suggest that Pank2 deficiency promotes an increased oxidative status that is further enhanced by the addition of iron, potentially causing damage in cells.
IIT Network, Research Unit of Molecular Neuroscience, Milano, Italy.
Alessandro
A
Campanella
Daniela
D
Privitera
Michela
M
Guaraldo
Elisabetta
E
Rovelli
Chiara
C
Barzaghi
Barbara
B
Garavaglia
Paolo
P
Santambrogio
Anna
A
Cozzi
Sonia
S
Levi
D016022:Case-Control Studies; D002374:Catalase / Q000378:metabolism; D002478:Cells, Cultured; D005293:Ferritins / Q000378:metabolism; D005347:Fibroblasts / Q000201:enzymology / Q000378:metabolism*; D006801:Humans; D007501:Iron / Q000378:metabolism*; D035925:Iron-Regulatory Proteins / Q000378:metabolism; D020125:Mutation, Missense; D010084:Oxidation-Reduction; D018384:Oxidative Stress; D006211:Pantothenate Kinase-Associated Neurodegeneration / Q000378:metabolism / Q000473:pathology*; D017853:Phosphotransferases (Alcohol Group Acceptor) / Q000172:deficiency / Q000235:genetics*; D011485:Protein Binding; D050050:Protein Carbonylation; D012867:Skin / Q000473:pathology*; D013482:Superoxide Dismutase / Q000378:metabolism; D000072105:Superoxide Dismutase-1
D035925:Iron-Regulatory Proteins; C000606290:SOD1 protein, human; D005293:Ferritins; D007501:Iron; D002374:Catalase; D013482:Superoxide Dismutase; D000072105:Superoxide Dismutase-1; D017853:Phosphotransferases (Alcohol Group Acceptor); C023088:pantothenate kinase